Application of biomarker TSPAN7 in diagnosis and treatment of pancreatic cancer
Through the TSPAN7 gene and its expression products as biomarkers, the problems of early diagnosis and treatment of pancreatic cancer are solved, high sensitivity and specific diagnosis of pancreatic cancer are achieved, and platinum chemotherapy is guided, which improves the survival prognosis of patients.
Patent Information
- Application Number
- CN202411194114.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-28
- Publication Date
- 2024-11-12
AI Technical Summary
The prior art is difficult to effectively diagnose and treat pancreatic cancer, especially early diagnosis and recurrent or metastatic pancreatic cancer are not effective for existing treatment options, and lacks sensitivity and specific biomarkers.
Using the TSPAN7 gene and its expression products as biomarkers, drug compositions are developed to enhance or regulate TSPAN7 expression by detecting the expression level of TSPAN7 in pancreatic cancer tissues, for the diagnosis and treatment of pancreatic cancer, and to guide platinum chemotherapy sensitivity.
By detecting TSPAN7 expression levels, predict the sensitivity and specificity of the patient to platinum chemotherapy, provide individualized treatment plans, and improve the survival prognosis of patients.
Smart Images

Figure CN118924918A_ABST
